Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.31 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7065748 | 0.92 | KDM4E (0.31) | — | |
| SCHEMBL7070572 | 0.89 | GPR84 (0.35) | — | |
| SCHEMBL7006066 | 0.89 | GPR84 (0.35) | — | |
| SCHEMBL7006346 | 0.88 | — | — | |
| SCHEMBL8719172 | 0.86 | ABCC8 (0.31) | ABCC8KCNJ11 | |
| SCHEMBL7496724 | 0.84 | ADRA2A (0.37) | ADRA2AADRA2BADRA2CMAPT | |
| SCHEMBL7069104 | 0.82 | ESR1 (0.36) | — | |
| SCHEMBL7067549 | 0.82 | — | — | |
| SCHEMBL7075500 | 0.81 | ABCC8 (0.32) | ABCC8KCNJ11 | |
| SCHEMBL7068597 | 0.80 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003105896-A1 | COMBINED USE OF A MODULATOR OF CD3 AND A BETA CELL RESTING COMPOUND | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | claimed |
| WO-2003045954-A1 | USE OF SELECTIVE POTASSIUM CHANNEL OPENERS | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | WO | claimed |
| WO-2003045955-A1 | USE OF SELECTIVE POTASSIUM CHANNEL OPENERS | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | WO | claimed |
| WO-2002000222-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | claimed |
| WO-2002000223-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | claimed |
| EP-0876379-A1 | FUSED 1,2,4-THIADIAZINE AND FUSED 1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1998-11-11 | — | — | EP | claimed |
| WO-1997026265-A1 | FUSED 1,2,4-THIADIAZINE AND FUSED 1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1997-07-24 | — | — | WO | claimed |
| WO-2003105896-A1 | COMBINED USE OF A MODULATOR OF CD3 AND A BETA CELL RESTING COMPOUND | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003045955-A1 | USE OF SELECTIVE POTASSIUM CHANNEL OPENERS | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | WO | disclosed |
| WO-2002000222-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
| WO-2002000223-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |